JUNSHI BIO (01877) surged over 9%, and as of press time, the stock was up 8.36% to HK$38.36 with a turnover of HK$173 million.

On the news front, JUNSHI BIO announced that its recombinant humanized anti-IL-17A monoclonal antibody (code: JS005) recently achieved positive results in a multicenter, randomized, double-blind, parallel, placebo-controlled pivotal registration Phase III clinical trial (study number: JS005-005-III-PsO) for the treatment of moderate to severe plaque psoriasis. Both co-primary endpoints and key secondary endpoints demonstrated statistically significant and clinically meaningful improvements. The company plans to submit a marketing authorization application to regulatory authorities in the near future.

According to the introduction, JS005 is a proprietary anti-IL-17A monoclonal antibody independently developed by the company. As of the disclosure date of this announcement, this multicenter, randomized, double-blind, parallel, placebo-controlled pivotal registration Phase III clinical trial (study number: JS005-005-III-PsO) for JS005 has been successfully completed and achieved its co-primary endpoints and key secondary endpoints.

The study results showed that compared to placebo, JS005 significantly improved participants' psoriasis lesion area and severity. The proportion of participants achieving an sPGA score of 0 or 1 was significantly superior to placebo, and the drug demonstrated good safety in participants with moderate to severe plaque psoriasis. The relevant research results are planned to be published at future international academic conferences.